Jubbonti ® (denosumab-bbdz) and Wyost ® (denosumab-bbdz), interchangeable biosimilars to Prolia ® (denosumab) and Xgeva ® (denosumab), respectively, are now available from Sandoz. The ...

Investigators presented an interim analysis of the phase 3 ENLIGHTED trial of photodynamic therapy in patients with low-grade upper-tract urothelial cancer.

Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin (BCG) is as safe and effective as BCG alone for patients with high-risk non-muscle invasive bladder ...

Rapid reduction of glucocorticoid (GC) doses to 7.5 mg/day or less within 6 months may not worsen renal outcomes or increase relapse in patients with proliferative lupus nephritis (LN), recent study ...

Investigators created a prognostic digital pathology-based AI score to identify a subset of patients with clinically high-risk prostate cancer more likely to benefit from the addition of abiraterone ...

The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights.

Medical AI tools for clinicians and patients have advantages and disadvantages, including implicit bias in triage and virtual urgent care.

PARP inhibitors demonstrate synergy with radiation, so investigators tested the efficacy and safety of olaparib plus radium-223 in patients with mCRPC and bone metastases in a phase 2 trial.

Real-world data confirm PSA cutoffs for prognosis in patients treated for metastatic hormone-sensitive prostate cancer.

Investigators evaluated the effectiveness of an immunotherapy in combination with standard radiation therapy for patients with intermediate-high risk localized prostate cancer.

AMPLITUDE is the “first trial to show efficacy for the combination of inhibition of PARP and the androgen receptor pathway in metastatic, castration-sensitive prostate cancer with alteration of genes ...

One-year incidence of psychosocial therapy initiation was 12.6 percent, while incidence of medication initiation was 2.8 percent ...